A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C - PubMed
Randomized Controlled Trial
. 2007 Nov;103(1-3):83-90.
doi: 10.1016/j.jad.2007.01.007. Epub 2007 Feb 9.
Affiliations
- PMID: 17292481
- DOI: 10.1016/j.jad.2007.01.007
Randomized Controlled Trial
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C
Benjamin J Morasco et al. J Affect Disord. 2007 Nov.
Erratum in
- J Affect Disord. 2009 Feb;113(1-2):201
Abstract
Background: Interferon-alpha-(IFN-alpha) induced depression presents a challenge when treating patients with the hepatitis C virus (HCV). Depression occurs in approximately one-third of patients during antiviral therapy and can lead to reduction in treatment dosage or discontinuation of treatment, thus reducing the likelihood of clearing HCV infection. This study examined the efficacy of paroxetine in preventing the development of depression during antiviral therapy.
Methods: In a double-blind, placebo-controlled study, 33 patients with HCV were randomly assigned to paroxetine or placebo prior to antiviral therapy. Patients were evaluated for psychiatric symptoms prior, during, and six months after antiviral therapy.
Results: The rate of IFN-alpha-induced depression for the entire sample was 33.3%. The prophylactic use of paroxetine did not decrease the likelihood of IFN-alpha-induced depression (35.7% in the paroxetine group vs. 31.6% in the placebo group). However, in 10 of 11 patients who developed IFN-alpha-induced depression and entered the rescue arm of the study, open-label treatment with paroxetine helped reduce symptoms of depression. Group assignment did not appear to impact antiviral therapy completion rates, as a similar proportion of patients from each group completed treatment.
Limitations: The antiviral treatment was changed during the trial and aspects of the sample limit the generalizability of the results.
Conclusion: A prophylactic approach to interferon-alpha-induced depression may not be indicated in patients with HCV infection.
Similar articles
-
Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T. Schaefer M, et al. J Hepatol. 2005 Jun;42(6):793-8. doi: 10.1016/j.jhep.2005.01.020. Epub 2005 Apr 2. J Hepatol. 2005. PMID: 15885349 Clinical Trial.
-
Diez-Quevedo C, Masnou H, Planas R, Castellví P, Giménez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J. Diez-Quevedo C, et al. J Clin Psychiatry. 2011 Apr;72(4):522-8. doi: 10.4088/JCP.09m05282blu. Epub 2010 Oct 5. J Clin Psychiatry. 2011. PMID: 21034680 Clinical Trial.
-
Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Raison CL, et al. Aliment Pharmacol Ther. 2007 May 15;25(10):1163-74. doi: 10.1111/j.1365-2036.2007.03316.x. Aliment Pharmacol Ther. 2007. PMID: 17451562 Clinical Trial.
-
Can antidepressants prevent interferon-alpha-induced depression? A review of the literature.
Galvão-de Almeida A, Guindalini C, Batista-Neves S, de Oliveira IR, Miranda-Scippa A, Quarantini LC. Galvão-de Almeida A, et al. Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):401-5. doi: 10.1016/j.genhosppsych.2010.03.001. Epub 2010 Apr 2. Gen Hosp Psychiatry. 2010. PMID: 20633744 Review.
-
Asnis GM, De La Garza R 2nd. Asnis GM, et al. J Clin Gastroenterol. 2006 Apr;40(4):322-35. doi: 10.1097/01.mcg.0000210099.36500.fe. J Clin Gastroenterol. 2006. PMID: 16633105 Review.
Cited by
-
Li J, Huang S, Huang W, Wang W, Wen G, Gao L, Fu X, Wang M, Liang W, Kwan HY, Zhao X, Lv Z. Li J, et al. Oncotarget. 2017 Jan 31;8(5):8264-8282. doi: 10.18632/oncotarget.14160. Oncotarget. 2017. PMID: 28030814 Free PMC article.
-
Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Morasco BJ, et al. Psychosomatics. 2010 Sep-Oct;51(5):401-8. doi: 10.1176/appi.psy.51.5.401. Psychosomatics. 2010. PMID: 20833939 Free PMC article. Clinical Trial.
-
Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV?
Rowan PJ. Rowan PJ. World J Virol. 2013 Nov 12;2(4):139-45. doi: 10.5501/wjv.v2.i4.139. World J Virol. 2013. PMID: 24255885 Free PMC article. Review.
-
Delicate Situation of Bipolar Disorder and Interferon Therapy.
Aarab C, Aalouane R, Boujraf S, Rammouz I. Aarab C, et al. J Neurosci Rural Pract. 2018 Jan-Mar;9(1):164-166. doi: 10.4103/jnrp.jnrp_179_17. J Neurosci Rural Pract. 2018. PMID: 29456366 Free PMC article. No abstract available.
-
McNutt MD, Liu S, Manatunga A, Royster EB, Raison CL, Woolwine BJ, Demetrashvili MF, Miller AH, Musselman DL. McNutt MD, et al. Neuropsychopharmacology. 2012 May;37(6):1444-54. doi: 10.1038/npp.2011.330. Epub 2012 Feb 22. Neuropsychopharmacology. 2012. PMID: 22353759 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical